On the Record · Bioverativ
Bioverativ acquisitions, on the record
The businesses Bioverativ bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Syntonix PharmaceuticalsWord for word“In January 2007, Biogen acquired 100% of the stock of Syntonix Pharmaceuticals (Syntonix).” 10-K for 2016 | acquisition | January 2007 | — |
True North Therapeutics, Inc.Word for word“True North Acquisition - On June 28, 2017, we acquired all of the outstanding equity of True North Therapeutics, Inc. (True North), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class product candidates for complement-mediated diseases.” 10-K for 2017 | acquisition | On June 28, 2017 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) |
|---|---|
| 2017-12-31 | $395.7 million |
Deal filings since 2016
- 2018-03-08 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2018-01-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-06-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-06-29 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2017-05-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-02-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Bioverativ’s annual reports (10-K for 2017, 10-K for 2016) and the financial data it files with the SEC, as of 2018-02-14. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.